View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports

Johnson & Johnson: 1 director

A director at Johnson & Johnson maiden bought 1,000 shares at 147.220USD and the significance rating of the trade was 63/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two ye...

Boston Scientific Corp: 1 director

A director at Boston Scientific Corp sold/sold after exercising options 14,010 shares at 89.269USD and the significance rating of the trade was 80/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's dire...

Boston Scientific Corporation: Update to credit analysis following out...

Our credit view of this issuer reflects its leading position in key markets and its broad product and geographic diversification, against its ongoing appetite for acquisitions

MarketLine Department
  • MarketLine Department

Standard Chartered Private Bank - Company Profile and SWOT Analysis

Summary Standard Chartered Private Bank - Company Profile and SWOT Analysis, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company. Key Highlights Standard Chartered Private Bank (SCPB) is the private banking arm of Standard Chartered Bank (Singapore) Limited and offers wealth management, sustainable investing, legacy planning, and...

Johnson & Johnson - June 2024 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

Johnson & Johnson: Key facts and statistics - LTM June 2024

A summary company profile, detailing Johnson & Johnson’s business operations and financial highlights.

Boston Scientific Corporation: Key facts and statistics - LTM March 20...

A summary company profile, detailing Boston Scientific Corporation’s business operations and financial highlights.

Johnson & Johnson - March 2024 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Short Shots: Technically Vulnerable Stocks

Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.

Research Team ACF
  • Research Team ACF

Regenerative Healthcare - Stem Cells & ALS Thematic 10062024

Regenerative medicine remains an extremely exciting area of healthcare with vast investment potential. In spite of the usual setbacks in valuation and strategy, the sub-sector has pivoted and the market remains innovative and attracts investment capital. Rather than replace entire tissues, which is a complex activity, we believe the immediate future for stem cells is more likely to be in the successful stimulation of the bodies on repair mechanisms. Within regenerative medicine we believe there ...

Moody's Ratings assigns Aaa ratings to Johnson & Johnson's sr. notes; ...

Moody's Ratings (Moody's) assigned Aaa ratings to the new USD and EUR denominated senior unsecured note offerings of Johnson & Johnson ("J&J"). There are no changes to J&J's existing ratings including the Aaa senior unsecured long-term rating or the Prime-1 short-term rating. The outlook remains unc...

Johnson & Johnson: Update following ratings affirmation

Our credit view of this issuer reflects its strong global scale and diversity and conservative financial policies, offset by unresolved talc litigation exposures.

Moody's Ratings affirms J&J's Aaa ratings; stable outlook

Moody's Ratings (Moody's) affirmed the ratings of Johnson & Johnson ("J&J") including the Aaa long-term issuer rating, Aaa senior unsecured rating, (P)Aaa senior unsecured medium term note program rating and Prime-1 commercial paper rating. The outlook remains stable. This rating action follows th...

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch